

XhoI AseI
 1 CTCGAGAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTAT
 EcoRI RBS
 79 GCTCCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTTCACACAGAATTCATTAAAGAGGAGAAATTAAC
 PelB leader AlwNI NcoI Serum A
 157 CATGAAATACCTATTGCCTACGGCAGCCGCTGGCTTGCTGCTGCTGGCAGCTCAGCCGCCATGGCGCAGGTGCAGCTG
 1 MetAlaGlnValGlnLeu
 VH anti-CD16 EcoRV
 235 CAGCAGTCTGGAGCTGAGCTGGTAAGGCCTGGGACTTCAGTGAAGATATCCTGCAAGGCTTCTGGCTACACCTTCACCT
 7 GlnGlnSerGlyAlaGluLeuValArgProGlyThrSerValLysIleSerCysLysAlaSerGlyTyrThrPheThr
 CDR-H1 EcoRV CDR-H2
 313 AACTACTGGCTAGGTTGGGTAAAACAGAGGCCTGGACATGGACTCGAGTGGATTGGAGATATCTACCCTGGAGGTGGT
 33 AsnTyrTrpLeuGlyTrpValLysGlnArgProGlyHisGlyLeuGluTrpIleGlyAspIleTyrProGlyGlyGly
 391 TATACTAACTACAATGAGAAATCAAGGCCAAGCCACAGTGCAGACACATCCTCCAGAACTGCCTACGTGCAG
 59 TyrThrAsnTyrAsnGluLysPheLysGlyLysAlaThrValThrAlaAspThrSerSerArgThrAlaTyrValGln
 CDR-H3
 469 GTCAGGAGCCTGACATCTGAGGACTCTGCTGTCTATTTCTGTGCAAGATCCGGCTAGCTGGTACTTCCATGTCTGGGGC
 85 ValArgSerLeuThrSerGluAspSerAlaValTyrPheCysAlaArgSerAlaSerTrpTyrPheAspValTrpGly
 CH1 HindIII Linker EcoRV
 547 GCACGGACTACGGTCACCGTCTCCTCAGCCAAAACAACACCCAAGCTTGGCGGTGATATCGAGCTCACTCAGTCTCCA
 111 AlaArgThrThrValThrValSerSerAlaLysThrThrProLysLeuGlyGlyAspIleGluLeuThrGlnSerPro
 VL anti-CD30
 625 AAATTCATGTCCACATCAGTAGGAGACAGGGTCAACGTCACCTACAAGGCCAGTCAGAATGTGGGTACTAATGTAGCC
 137 LysPheMetSerThrSerValGlyAspArgValAsnValThrTyrLysAlaSerGlnAsnValGlyThrAsnValAla
 703 TGGTTTCAACAAAACCAGGGCAATCTCCTAAAGTTCTGATTACTCGGCATCTTACCGATACAGTGGAGTCCCTGAT
 163 TrpPheGlnGlnLysProGlyGlnSerProLysValLeuIleTyrSerAlaSerTyrArgTyrSerGlyValProAsp
 781 CGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAGCAATGTGCAGTCTGAAGACTTGGCAGAGTAT
 189 ArgPheThrGlySerGlySerGlyThrAspPheThrLeuThrIleSerAsnValGlnSerGluAspLeuAlaGluTyr
 C kappa NotI
 859 TTCTGTCAGCAATATCACACCTATCCTCTCACGTTCCGAGGGGGCACCAAGCTGGAAATCAAACGGGCTGATGCTGCG
 215 PheCysGlnGlnTyrHisThrTyrProLeuThrPheGlyGlyGlyThrLysLeuGluIleLysArgAlaAspAlaAla
 BamHI c-myc epitope His6 tail BglII
 937 GCCGCTGGATCCGAACAAAAGCTGATCTCAGAAGAAGACCTAAACTCACATCACCATCACCATCACTAAAGATCTATT
 241 AlaAlaGlySerGluGlnLysLeuIleSerGluGluAspLeuAsnSerHisHisHisHisHis
 RBS Pel B leader NcoI
 1015 AAAGAGGAGAAATTAACCATGAAATACCTATTGCCTACGGCAGCCGCTGGCTTGCTGCTGCTGGCAGCTCAGCCGGCC
 NcoI Serum A VH anti-CD30
 1093 ATGGCGGCCATGGCCAGGTGCAACTGCAGCAGTCAGGGGCTGAGCTGGCTAGACCTGGGGCTTCAGTGAAGATGTCC
 1 MetAlaGlnValGlnLeuGlnGlnSerGlyAlaGluLeuAlaArgProGlyAlaSerValLysMetSer
 1171 TGCAAGGCTTCTGGCTACACCTTTACTACCTACACAATACACTGGGTAAGACAGAGGCCCTGGACACGATCTGGAATGG
 24 CysLysAlaSerGlyTyrThrPheThrThrTyrThrIleHisTrpValArgGlnArgProGlyHisAspLeuGluTrp
 1249 ATTGGATACATTAATCCTAGCAGTGGATATTCTGACTACAATCAGAACTTCAAGGGCAAGACCACATTGACTGCAGAC
 50 IleGlyTyrIleAsnProSerSerGlyTyrSerAspTyrAsnGlnAsnPheLysGlyLysThrThrLeuAlaAsp
 1327 AAGTCTCCAACACAGCCTACATGCAACTGAACAGCCTGACATCTGAGGACTCTCGGGTCTATTACTGTGCAAGAAGA
 76 LysSerSerAsnThrAlaTyrMetGlnLeuAsnSerLeuThrSerGluAspSerAlaValTyrTyrCysAlaArgArg
 CH1
 1405 GCGGACTATGGTAACACGAATATACCTGGTTTGCTTACTGGGGCCAAGGGACCAGGTCACCGTCTCCTCAGCCAAA
 102 AlaAspTyrGlyAsnTyrGluTyrThrTrpPheAlaTyrTrpGlyGlnGlyThrThrValThrValSerSerAlaLys
 HindIII Linker EcoRV VL anti-CD16
 1483 ACAACACCCAAGCTTGGCGGTGATATCCAGGCTGTTGTGACTCAGGAATCTGCACTCACCACATCACCTGGTGAAC
 128 ThrThrProLysLeuGlyGlyAspIleGlnAlaValValThrGlnGluSerAlaLeuThrThrSerProGlyGluTh
 CDR-L1
 1560 AGTCACACTCACTTGTTCGCTCAAATACTGGGACTGTTACAATACTAGTAACTATGCCAACTGGGTCCAAGAAAAACCAGA
 153 rValThrLeuThrCysArgSerAsnThrGlyThrValThrThrSerAsnTyrAlaAsnTrpValGlnGluLysProAs
 CDR-L2
 1638 TCATTTATTCACCTGGTCTAATAGGTCAATACCAACAACCGAGCTCCAGGTGTTCTGCGCAGATTCTCAGGCTCCCTGAT
 179 pHisLeuPheThrGlyLeuIleGlyHisThrAsnAsnArgAlaProGlyValProAlaArgPheSerGlySerLeuIl
 CDR-L3
 1716 TGGAGACAAGGCTGCCCTCACCATCACAGGGGCACAGACTGAGGATGAGGCAATATATTTCTGTCTCTATGGTATAA
 205 eGlyAspLysAlaAlaLeuThrIleThrGlyAlaGlnThrGluAspGluAlaIleTyrPheCysAlaLeuTrpTyrAs
 NotI BamHI
 1794 CAACCATTTGGGTGTTTCGGTGGAGGAACCAAACTGACTGTCCTAGGCCAGCCCAAGTCTGCGGCCGCTGGATCCGAACA
 231 nAsnHisTrpValPheGlyGlyGlyThrLysLeuThrValLeuGlyGlnProLysSerAlaAlaAlaGlySerGluGl

Fig. 1

1872 AAAGCTGATCTCAGAAGAAGACCTAAACTCAGATCACCATCACCATCCTAATCTAGAGGCCTGTGCTAATGATCAGC
257 nLysLeuIleSerGluGluAspLeuAsnSerHisHisHisHisHisHisHis

1950 TAGCTTGAGGCATCAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTTCGTTTTATCTGTTGTTTGTGCGGTTAAC
Sall EarI PvuI FspI BglI

2028 GTCGACCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGA
2106 CGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT

2184 AGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTTCGCCGGCTTTCCCGTCAAGCTCTAAATCGGGG
f1 IR DralI

2262 GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACCTTGATTAGGGTGATGGTTTCACGTAG
2340 TGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCA
2418 AACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTT

2496 AAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTT
BspHI

2574 CGGGGAAATGTGCGCGGAACCCCTATTTGTTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAA
SspI EarI

2652 CCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCGCCCTTATTCCCTTT
ApaI

2730 TTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGT
Xmnl

2808 GCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCGCAAGAACGTTTTCCA
DraI

2886 ATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCG
ScaI 1000

2964 CGCATACACTATTCTCAGAAATGACTTGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGATGGCATGACAGTA
β-Lactamase PvuI

3042 AGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCG
3120 AAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCCTTGATCGTTGGGAACCGGAGCTGAATGAA
FspI

3198 GCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAAGTGGCGAA
AseI

3276 CTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGACAGGACCACTTCTGCGCTCG
BglI BsaI

3354 GCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTG
3432 GGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA
3510 CAGATCGCTGAGATAGGTGCCTCACTGATTAAAGCATTTGGTAACTGTGACACCAAGTTTACTCATATATACTTTAGATT
DraI DraI BspHI

3588 GATTTAAAACTTCATTTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAA
3666 CGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGC
3744 GTAATCTGCTGCTTGCAAAACAAAAAACCCGCTACCAGCGGTGGTTTGTGTTGCGGATCAAGAGCTACCAACTCTT
3822 TTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
AlwNI

3900 TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAG
ColE1 2000 ApaLI

3978 TCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGTCCGGCTGAACGGGGGGTTCGTGC
4056 ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTT
4134 CCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCAGGGAGCTTCCAGGG
4212 GGAAACGCCTGGTATCTTTATAGTCTGTGCGGTTTTGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCA
4290 GGGGGGCGGAGCCTATGGAACAAACGCCAGCAACGCGGCCTTTTTACGGTTCTTGGCCTTTTGCTGGCCTTTTGCTCAC
4368 ATGTTCTTTCTGCGTTATCCCCCTGATTTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCCGC
EarI


4446 AGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCG
AseI BspMI

4524 CGTTGGCCGATTCAATTAATGCAGGTATCACGAGGCCCTTTTCGTCTTCAC




Fig. 2

Granulocytes (CD16⁺)L540CY cells (CD30⁺)

Neg. Control



Neg. Control

F_v antibody construct
according to the inventionF_v antibody construct
according to the invention

Fluorescence Intensity

Fig. 3




Fig. 4

